All In Biotech

Drug Trial Radar · NCT07502560

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

A Randomized, Placebo Controlled, Observer-blind, Phase IV Pragmatic Trial to Evaluate the Effect of Recombinant Zoster Vaccine (Shingrix) on Incident Dementia Diagnosis in an Older Adult Population Aged ≥76 Years in Finland

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 33,609 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

33,609

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Apr 1, 2030

Study completion Mar 31, 2037

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Finnish Vaccine Research;; Dr Arto Palmu
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 76 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.

Conditions

  • Herpes Zoster

Interventions

  • Recombinant zoster vaccineBiological

    Recombinant zoster vaccine administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose), according to the approved recombinant zoster vaccine dosing schedule.

  • PlaceboDrug

    Placebo administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hazard ratio of incident dementia diagnosisTime frame: From first dose of study intervention (Day 1) until the date of first dementia diagnosis, death, loss to follow-up, or end of data availability, whichever occurs first, assessed up to 10 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Espoo, Finland · Recruiting

  • GSK Investigational Site

    Helsinki, Finland · Recruiting

  • GSK Investigational Site

    Jarvenpaa, Finland · Recruiting

  • GSK Investigational Site

    Kokkola, Finland · Recruiting

  • GSK Investigational Site

    Oulu, Finland · Recruiting

  • GSK Investigational Site

    Seinäjoki, Finland · Recruiting

  • GSK Investigational Site

    Tampere, Finland · Recruiting

  • GSK Investigational Site

    Turku, Finland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.